Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $48.7 million.

  • Mereo BioPharma's Cash & Equivalents fell 3951.96% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.7 million, marking a year-over-year decrease of 3951.96%. This contributed to the annual value of $69.8 million for FY2024, which is 2156.18% up from last year.
  • As of Q3 2025, Mereo BioPharma's Cash & Equivalents stood at $48.7 million, which was down 3951.96% from $56.1 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Cash & Equivalents registered a high of $127.1 million during Q4 2021, and its lowest value of $32.8 million during Q2 2021.
  • Its 5-year average for Cash & Equivalents is $71.5 million, with a median of $65.3 million in 2022.
  • Per our database at Business Quant, Mereo BioPharma's Cash & Equivalents surged by 31017.55% in 2021 and then crashed by 4636.07% in 2022.
  • Mereo BioPharma's Cash & Equivalents (Quarter) stood at $127.1 million in 2021, then tumbled by 46.36% to $68.2 million in 2022, then decreased by 15.78% to $57.4 million in 2023, then increased by 21.56% to $69.8 million in 2024, then plummeted by 30.23% to $48.7 million in 2025.
  • Its Cash & Equivalents was $48.7 million in Q3 2025, compared to $56.1 million in Q2 2025 and $62.5 million in Q1 2025.